Sentiment for Rare Hospitality International Inc (NASDAQ:RARE)
Rare Hospitality International Inc (NASDAQ:RARE) institutional sentiment decreased to 1.5 in Q2 2019. Its down -1.08, from 2.58 in 2019Q1. The ratio dropped, as 84 institutional investors increased or started new positions, while 56 sold and decreased their equity positions in Rare Hospitality International Inc. The institutional investors in our partner’s database reported: 57.68 million shares, up from 57.27 million shares in 2019Q1. Also, the number of institutional investors holding Rare Hospitality International Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 20 Reduced: 36 Increased: 61 New Position: 23.
Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company has market cap of $2.47 billion. The firm is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It currently has negative earnings. The Company’s biologics product candidates also comprise recombinant human beta -glucuronidase , an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis.
The stock increased 2.78% or $1.15 during the last trading session, reaching $42.72. About 613,983 shares traded. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has declined 22.30% since December 4, 2018 and is downtrending. It has underperformed by 22.30% the S&P500.
Analysts await Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to report earnings on February, 18. They expect $-1.65 earnings per share, up 4.62 % or $0.08 from last year’s $-1.73 per share. After $-1.96 actual earnings per share reported by Ultragenyx Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts -15.82 % EPS growth.
Ecor1 Capital Llc holds 3.19% of its portfolio in Ultragenyx Pharmaceutical Inc. for 497,899 shares. Highline Capital Management L.P. owns 390,453 shares or 1.81% of their US portfolio. Moreover, First Light Asset Management Llc has 1.59% invested in the company for 180,017 shares. The Maryland-based Rock Springs Capital Management Lp has invested 1.33% in the stock. Capital Impact Advisors Llc, a Massachusetts-based fund reported 36,165 shares.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Ratings Coverage
Ratings analysis reveals 75% of Ultragenyx Pharmaceutical’s analysts are positive. Out of 4 Wall Street analysts rating Ultragenyx Pharmaceutical, 3 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $4500 while the high is $8000. The stock’s average target of $69 is 61.52% above today’s ($42.72) share price. RARE was included in 7 notes of analysts from August 2, 2019. The stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has “Market Outperform” rating given on Wednesday, November 6 by JMP Securities. On Wednesday, November 6 the stock rating was maintained by Morgan Stanley with “Overweight”. On Friday, August 2 the stock rating was reinitiated by Wedbush with “Outperform”. The firm has “Neutral” rating by Citigroup given on Thursday, November 7. The firm has “Overweight” rating by Morgan Stanley given on Friday, August 2.
More notable recent Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) news were published by: Nasdaq.com which released: “U.S. STOCKS ON THE MOVE-General Electric, Cymabay, TD Ameritrade, Uber – Nasdaq” on November 25, 2019, also Nasdaq.com with their article: “BUZZ-U.S. STOCKS ON THE MOVE-Chip and oil stocks, DarioHealth, Aslan Pharmaceuticals, Outlook Therapeutics – Nasdaq” published on December 03, 2019, Nasdaq.com published: “Avoid These 3 Mutual Fund Misfires – November 28, 2019 – Nasdaq” on November 28, 2019. More interesting news about Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) were released by: Nasdaq.com and their article: “Here’s Why Vertex Pharmaceuticals Rose 13.4% in November – Nasdaq” published on December 04, 2019 as well as Nasdaq.com‘s news article titled: “Ontario focused on rare disease drugs ahead of national drug plan talks – Nasdaq” with publication date: December 02, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.